Tuesday, June, 25, 2019 08:15:47

Contribution By Shikha Sinha


United Therapeutics invests $800M upfront in Arena’s PAH drug

U.S. biotechnology firm, United Therapeutics Corp. has recently invested $800 million cash upfront to grab rights to Arena Pharmaceuticals’ pulmonary arterial hypertension (PAH) drug, Ralinepag. As per sources, the firm’s executive crew believes that the acquired rights would enable the company to gain huge revenues …

India and the UK ink MoU to conjointly work on cancer research

The Ministry of Science and Technology has recently announced that India and the United Kingdom have both signed a Memorandum of Understanding (MoU) for collaborating on cancer research at the Inaugural Researchers’ Conference in New Delhi. The India-UK Cancer Research Initiative focused on developing affordable …

IMV joins Merck to gauge DPX-Survivac, declares Phase 2 basket trial

IMV Incorporation, a clinical stage biopharmaceutical company, has reportedly declared the expansion of its clinical program through a Phase 2 basket trial assessing its prime drug, DPX-Survivac, combined with KEYTRUDA (pembrolizumab) and cyclophosphamide, in patients suffering from recurrent or advanced solid tumors. Frederic Ors, Chief …

Pfizer’s inhibitor drug given Breakthrough Therapy designation by FDA

Pfizer recently made an announcement confirming that its experimental oral inhibitor, Janus kinase 3 (JAK3) or PF-06651600, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Apparently, the inhibitor is being developed for treating patients suffering from alopecia areata, …

CHAOS approach taps CRISPR to alter multiple genes in bacterial cells

Researchers at the University of Colorado Boulder have reportedly developed an unconventional genetic disruption strategy that successfully stymies the growth of antibiotic-resistant bacteria, giving scientists an edge over deadly superbugs. According to data from the Centers for Disease Control, these multiple drug resistant pathogens — …